PapersFlow Research Brief
Thyroid Cancer Diagnosis and Treatment
Research Guide
What is Thyroid Cancer Diagnosis and Treatment?
Thyroid Cancer Diagnosis and Treatment refers to the evidence-based clinical processes for detecting thyroid nodules, confirming differentiated thyroid cancer through biopsy and imaging, and managing it via surgery, radioactive iodine therapy, and long-term monitoring as outlined in American Thyroid Association guidelines.
There are 99,121 works on thyroid cancer diagnosis and treatment in the literature. The 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer provide evidence-based recommendations for clinical decision-making in managing thyroid nodules and differentiated thyroid cancer, representing contemporary optimal care. The Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer from 2009 similarly offer recommendations to assist in clinical management.
Research Sub-Topics
Thyroid Nodule Ultrasound Evaluation
This sub-topic covers ultrasound patterns, elastography, and risk stratification systems like TI-RADS for thyroid nodules. Researchers validate imaging criteria against biopsy outcomes.
Papillary Thyroid Carcinoma Genomics
This sub-topic examines BRAF, RAS, RET/PTC mutations and gene expression profiles in papillary thyroid cancer. Researchers correlate genomic alterations with clinical behavior and targeted therapies.
Differentiated Thyroid Cancer Radioiodine Therapy
This sub-topic studies 131I dosimetry, remnant ablation, adjuvant therapy, and treatment optimization protocols. Researchers address stunning, dosimetry, and long-term outcomes.
Medullary Thyroid Carcinoma Genetics
This sub-topic focuses on RET proto-oncogene mutations, familial syndromes, and hereditary MTC screening. Researchers develop genotype-phenotype correlations and prophylactic strategies.
Thyroid Cancer Active Surveillance
This sub-topic investigates observation protocols for low-risk papillary microcarcinomas avoiding immediate surgery. Researchers track growth rates, risk stratification, and quality of life outcomes.
Why It Matters
Thyroid cancer diagnosis and treatment directly impacts patient outcomes through standardized protocols that reduce overtreatment of indolent cancers while ensuring aggressive management of high-risk cases. Haugen et al. (2015) in "2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer" established guidelines adopted widely, influencing over 15,886 citing studies and standardizing care for differentiated thyroid cancer, the most common type. Davies and Welch (2006) documented a rising incidence from 1973-2002 due to increased detection of small papillary cancers, prompting refined diagnostic thresholds to avoid unnecessary interventions amid stable mortality. Recent developments include an AI model achieving over 90% accuracy in classifying thyroid cancer stage and risk, reducing consultation preparation time, and FDA approval of selpercatinib for thyroid cancers with RET mutations, as reported in Memorial Sloan Kettering treatments.
Reading Guide
Where to Start
"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer" by Haugen et al. (2015), as it provides the most-cited (15,886 times), comprehensive evidence-based framework for diagnosis, staging, treatment, and monitoring of thyroid nodules and differentiated thyroid cancer.
Key Papers Explained
Haugen et al. (2015) in "2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer" updates and refines Cooper et al. (2009) in "Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer," incorporating new evidence on risk stratification and active surveillance. Mazzaferri and Jhiang (1994) "Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer" provides foundational outcomes data supporting the surgical and radioiodine approaches emphasized in both guidelines. Agrawal et al. (2014) "Integrated Genomic Characterization of Papillary Thyroid Carcinoma" adds molecular insights that inform the precision elements in the 2015 guidelines.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
The 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer emphasize individualized care via the DATA framework (Diagnosis, risk/benefit Assessment, Treatment decisions, response Assessment), addressing staging, radioiodine debates, and patient-reported outcomes. Preprints like "Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management" integrate molecular profiling with conventional methods, while news highlights AI models with 90% accuracy for staging and targeted alpha therapy with astatine for radioiodine-refractory cases.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | 2015 American Thyroid Association Management Guidelines for Ad... | 2015 | Thyroid | 15.9K | ✓ |
| 2 | Revised American Thyroid Association Management Guidelines for... | 2009 | Thyroid | 6.7K | ✓ |
| 3 | Serum TSH, T<sub>4</sub>, and Thyroid Antibodies in the United... | 2002 | The Journal of Clinica... | 3.8K | ✕ |
| 4 | Increasing Incidence of Thyroid Cancer in the United States, 1... | 2006 | JAMA | 3.3K | ✕ |
| 5 | Integrated Genomic Characterization of Papillary Thyroid Carci... | 2014 | Cell | 3.0K | ✓ |
| 6 | Guidelines of the American Thyroid Association for the Diagnos... | 2011 | Thyroid | 2.9K | ✕ |
| 7 | The Colorado Thyroid Disease Prevalence Study | 2000 | Archives of Internal M... | 2.8K | ✕ |
| 8 | 2016 American Thyroid Association Guidelines for Diagnosis and... | 2016 | Thyroid | 2.7K | ✓ |
| 9 | THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM S... | 1977 | Clinical Endocrinology | 2.7K | ✕ |
| 10 | Long-term impact of initial surgical and medical therapy on pa... | 1994 | The American Journal o... | 2.6K | ✕ |
In the News
World’s first AI model for thyroid cancer diagnosis, gives 90% accuracy and reduced consultation preparation time
(LSHTM) has unveiled the world’’s first artificial intelligence (AI) model designed to classify both the cancer stage and risk category of thyroid cancer, achieving impressive accuracy exceeding 90%.
Next-Generation Targeted Alpha Therapy using Astatine ...
**Reston, VA (December 4, 2025)--**A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. ...
Latest Treatments and Research at MSK To Treat Thyroid ...
For Thyroid Cancers with RET Mutations, FDA Approves Selpercatinib
Improving Management and Treatment of Thyroid Cancer
Differentiated thyroid cancer is the most frequently diagnosed thyroid cancer in the U.S. Recently, the American Thyroid Association (ATA) released new practice guidelines for Differentiated thyroi...
ATA Research Grants - Duke Funding Opportunities
resources inaccessible for everyone.
Code & Tools
Implementation detail of our paper "Attention Based Multi-Instance Thyroid Cytopathological Diagnosis with Multi-Scale Feature Fusion" . ## Citati...
Incidence of primary thyroid cancer rises steadily over the past decades because of overdiagnosis and overtreatment through the improvement in imag...
## 👉 Table of Contents
This is the official implementation of "Narrative Feature or Structured Feature? A Study of Large Language Models to Identify Cancer Patients at Ri...
AI-Generated Content Enhanced Computer-Aided Diagnosis Model for Thyroid Nodules: A ChatGPT-Style Assistant|2024|arXiv|Disease diagnosis|Text, Imag...
Recent Preprints
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
staging and risk assessment, initial treatment decisions, assessment of treatment responses, monitoring approaches, diagnostic testing, and subsequent therapies based on the strength of evidence fo...
Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management
This review aims to provide a comprehensive and updated synthesis of thyroid cancer research, focusing on key aspects such as epidemiology, risk factors, diagnostic approaches, histological and mol...
The 2025 ATA guidelines for differentiated thyroid Cancer - Ten years of professional debate and measured progress
The ATA’s 2025 guidelines for differentiated thyroid cancer (DTC) management represent both continuity and change in how we approach patients with DTC \[ 1 \]. They appear at a time when thyroid ca...
Executive Summary of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.
guidelines emphasize individualized care through the DATA framework (Diagnosis, risk/benefit Assessment, Treatment decisions, and response… Expand
2025 ATA Differentiated Thyroid Cancer Guidelines: Risk stratification
**BACKGROUND**
Latest Developments
Recent developments in thyroid cancer diagnosis and treatment research include advances in targeted therapies, personalized treatment approaches, and new clinical guidelines, such as the 2025 ATA guidelines for differentiated thyroid cancer (UCSF, Springer). Notably, a promising immune-targeting vaccine, NOUS-209, has shown potential in intercepting cancer in individuals with Lynch Syndrome (MD Anderson). Additionally, research highlights the importance of molecular targeting, with FDA approval in 2018 for combination therapies in anaplastic thyroid cancer, and ongoing clinical trials exploring novel drugs like selpercatinib (NCI, UCLA). Overall, the focus is on early detection, precision medicine, and innovative therapies to improve patient outcomes (AACR).
Sources
Frequently Asked Questions
What are the key recommendations in the 2015 ATA guidelines for thyroid cancer management?
Haugen et al. (2015) developed evidence-based recommendations for managing thyroid nodules and differentiated thyroid cancer, covering diagnosis, staging, surgery, radioactive iodine therapy, and follow-up. These guidelines represent optimal care based on contemporary evidence. They have been cited 15,886 times, indicating broad clinical adoption.
How has the incidence of thyroid cancer changed in the United States?
Davies and Welch (2006) reported an increasing incidence of thyroid cancer from 1973-2002, primarily due to detection of small papillary cancers. This trend relates to a reservoir of subclinical cancers with stable overall mortality. The increase highlights the need for precise diagnostic criteria.
What role does serum TSH play in thyroid disease assessment?
Hollowell et al. (2002) measured serum TSH, T4, and thyroid antibodies in 17,353 U.S. individuals aged 12 and older via NHANES III, providing population reference data. These measurements inform thyroid nodule evaluation and cancer risk stratification. TSH levels guide biopsy decisions in guidelines.
What is the long-term impact of initial therapy on papillary and follicular thyroid cancer?
Mazzaferri and Jhiang (1994) examined outcomes after surgical and medical therapy for papillary and follicular thyroid cancer. Their findings support total thyroidectomy and radioactive iodine for better long-term survival in higher-risk patients. This work has 2,644 citations influencing treatment protocols.
How do ATA guidelines address thyroid disease in pregnancy?
Stagnaro-Green et al. (2011) provide evidence-based recommendations for diagnosing and managing thyroid disease during pregnancy and postpartum. These guidelines emphasize individualized care for thyroid nodules and cancer in pregnant patients. They offer optimal paradigms cited 2,923 times.
What genomic insights exist for papillary thyroid carcinoma?
Agrawal et al. (2014) conducted integrated genomic characterization of papillary thyroid carcinoma, identifying key mutations and alterations. This Cell paper with 2,962 citations informs molecular diagnostics and targeted therapies. It supports precision medicine in thyroid cancer treatment.
Open Research Questions
- ? How can diagnostic imaging and molecular testing be optimized to distinguish indolent from aggressive differentiated thyroid cancers amid rising incidence?
- ? What are the long-term effects of radioactive iodine therapy on quality of life and secondary malignancies in low-risk patients?
- ? How do genomic alterations in papillary thyroid carcinoma influence responses to emerging targeted therapies like selpercatinib?
- ? What refinements in risk stratification are needed for pregnancy-associated thyroid cancer management?
- ? How can AI and multimodal learning improve preoperative prediction of lymph node metastasis in primary thyroid cancer?
Recent Trends
The 2025 ATA guidelines update the 2015 version by Haugen et al., focusing on individualized DTC management amid plateaued incidence, with debates on radioiodine use and quality-of-life outcomes.
AI advancements include a model with over 90% accuracy for thyroid cancer staging and risk, plus deep multimodal learning for lymph node metastasis prediction in primary thyroid cancer.
Targeted therapies feature FDA-approved selpercatinib for RET-mutated cases and first-in-human astatine alpha therapy for iodine-refractory disease.
Research Thyroid Cancer Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Thyroid Cancer Diagnosis and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.